Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Polidocanol Microfoam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Polidocanol (1%) Microfoam (Varisolve) |
| Name | Type | Description |
|---|---|---|
| Polidocanol (1%) Microfoam (Varisolve) | DRUG | Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein. |
| Endovenous Microfoam Occlusion | PROCEDURE | Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries. |
Inclusion Criteria: * Males and females aged 18 to 60 with severe varicose veins, CEAP classes 3, 4 and 5 (CEAP is a classification and grading system for chronic venous disease) * Saphenofemoral junction (SFJ) incompetence. Retrograde blood flow in the GSV, greater than or equal to 1.0 second demo...
Polidocanol Microfoam is used for the treatment of varicose veins. It is a small molecule being developed by Boston Scientific Corporation (BSX) for this cardiovascular condition. The drug is currently in Phase 2 clinical development and is considered investigational, meaning it has not yet been approved by regulatory authorities.
Polidocanol Microfoam is being developed by Boston Scientific Corporation, a company traded on the New York Stock Exchange under the ticker symbol BSX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of varicose veins.
Polidocanol Microfoam is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of varicose veins. As of the available data, it has not received regulatory approval and remains in clinical testing.
Polidocanol Microfoam has been studied in one completed Phase 2 clinical trial with the identifier NCT00442364. This trial, titled 'Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt,' enrolled 60 participants in the United States. The study was uncontrolled and did not use randomization or blinding.
Polidocanol Microfoam is associated with the brand name Varisolve, as indicated by the clinical trial title 'Safety Study of Varisolve® Procedure for Treatment of Varicose Veins.' The investigational drug is being developed by Boston Scientific Corporation for the treatment of varicose veins.